natureresearch

Corresponding author(s):	NPJPARKD-00335R
Last updated by author(s):	2019.11.18

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics							
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.						
n/a Confirmed							
☐ ☐ The exact san	nple size (n) for each experimental group/condition, given as a discrete number and unit of measurement						
A statement of	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly						
The statistical Only common t	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.						
A description	A description of all covariates tested						
A description	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons						
A full descript AND variation	ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)						
For null hypot	thesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted is exact values whenever suitable.						
For Bayesian	analysis, information on the choice of priors and Markov chain Monte Carlo settings						
For hierarchic	al and complex designs, identification of the appropriate level for tests and full reporting of outcomes						
Estimates of e	effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated						
1	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.						
Software and o	code						
Policy information abo	ut <u>availability of computer code</u>						
Data collection	No software was used.						
Data analysis	SPSS 22.						
	om algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.						
Data							
Accession codes, unA list of figures that	ut <u>availability of data</u> include a <u>data availability statement</u> . This statement should provide the following information, where applicable: ique identifiers, or web links for publicly available datasets have associated raw data restrictions on data availability						
	e findings of this study are not publicly available due to restrictions by Norwegian data protection regulations. The data will be available author upon reasonable request.						
Field-speci	fic reporting						
Please select the one b	elow that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.						
∠ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences						

Life sciences study design

All studies must disclose on these points even when the disclosure is ne	negative.	⊃ is r	disclosure	the	when	even	points	these	on	disclose	must	studies	ДΙ
--	-----------	--------	------------	-----	------	------	--------	-------	----	----------	------	---------	----

urgery
ıded in
ator
L

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimenta	al systems Methods						
n/a Involved in the study	n/a Involved in the study						
Antibodies	ChIP-seq						
Eukaryotic cell lines	Flow cytometry						
Palaeontology	MRI-based neuroimaging						
Animals and other orga	Animals and other organisms						
Human research partici	Human research participants						
Clinical data							
Human research pa	rticipants						
Policy information about studi	es involving human research participants						
Population characteristics	Baseline charecteristics for age at surgery, gender, duration of disease at surgery, HAD, Mattis DRS, MDS-UPDRS I-IV, HY and LEDD for the whole population is included in the article.						
Recruitment	Between April 2009 and December 2013, 76 patients underwent STN-DBS surgery at Oslo University Hospital. Sixty patients (15 women, 45 men) participated in the study. Not included: 7 patients declined to participate, 4 were not included due to language barrier, one had psychiatric manifestations, one had chronic hip infection and three were not asked to participate.						
Ethics oversight Regional ethics committee (REK).							

Clinical data

Policy information about clinical studies

Note that full information on the approval of the study protocol must also be provided in the manuscript.

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions

Clinical trial registration	ClinicalTrials.gov Identifier: NCT00855621
Study protocol	Will be available from the corresponding author upon request.
Data collection	From 2009 to 2013, 60 patients referred for STN-DBS to the Department of Neurology, Oslo University Hospital, were included in a single-center randomized prospective study with double-blind comparison of the use of single sequential versus multiple simultaneous microelectrode-recordings to guide the placement of the permanent electrode. Patients were examined at the Dept of Neurology by a Neurologist specializing in movement disorders. Evaluations were performed preoperatively, 3 months and 12 months postoperatively.
Outcomes	The primary endpoints of the parent trial were the differences in scores from baseline to 1 year of STN-DBS, of MDS-UPDRS III medication-off and PDO-39.